Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.

Autor: Oing C; Haematology and Bone Marrow Transplantation with Division of Pneumology, Department of Oncology, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. c.oing@uke.de.; Laboratory of Radiation Biology and Experimental Radiation Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. c.oing@uke.de.; Division of Cancer Sciences, School of Medical Sciences, Translational Oncogenomics Group, The Manchester Cancer Research Centre, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK. c.oing@uke.de., Hentrich M; Department of Haematology and Oncology, Red Cross Hospital Munich, Munich, Germany., Lorch A; Department of Medical Oncology and Haematology, University Hospital Zurich, Zurich, Switzerland., Gläser D; Department of Internal Medicine III, Klinikum Suedstadt Rostock, Rostock, Germany., Rumpold H; Department of Internal Medicine II, Landeskrankenhaus Feldkirch, Feldkirch, Austria., Ochsenreither S; Charité Comprehensive Cancer Centre, Berlin, Germany.; Department of Medical Oncology and Hematology, Charité Campus Benjamin Franklin, Berlin, Germany., Richter S; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany., Dieing A; Department of Internal Medicine, Haematology and Oncology, Vivantes Hospital am Urban, Berlin, Germany., Zschäbitz S; Department of Medical Oncology, National Centre for Tumour Diseases, Heidelberg University Hospital, Heidelberg, Germany., Pereira RR; Division of Cancer Sciences, School of Medical Sciences, Translational Oncogenomics Group, The Manchester Cancer Research Centre, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Bokemeyer C; Haematology and Bone Marrow Transplantation with Division of Pneumology, Department of Oncology, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Seidel C; Haematology and Bone Marrow Transplantation with Division of Pneumology, Department of Oncology, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Jazyk: angličtina
Zdroj: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Feb; Vol. 146 (2), pp. 449-455. Date of Electronic Publication: 2019 Dec 14.
DOI: 10.1007/s00432-019-03071-2
Abstrakt: Purpose: Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinical case series of cabazitaxel treatment for platinum-refractory GCT.
Methods: Data of multiply relapsed GCT patients receiving single-agent cabazitaxel were retrospectively analysed. Endpoints included 12-week progression-free survival (PFS) rate, disease control rate, tumour marker responses, median PFS and OS, and toxicity.
Results: Cabazitaxel showed limited activity in 13 heavily pre-treated GCT patients. After a median follow-up of 23 weeks (IQR 29), 69% of patients were deceased. A median of 2 cycles of cabazitaxel (range 1-7) were applied. The 12-week PFS rate was 31%. Median PFS and OS were 7 and 23 weeks, respectively. Two patients achieved objective responses (15%), three patients (23%) achieved a tumour marker decline ≥ 50%, and the disease control rate was 39%. Cabazitaxel was well tolerated. CTCAE° III-IV haemato-toxicity was most common (54%), and dose reductions were scarce (15%).
Conclusion: In this case series, cabazitaxel showed limited activity in heavily pre-treated GCT patients. Two-phase II studies are underway (NCT02115165, NCT02478502) prospectively assessing cabazitaxel in multiply relapsed GCTs.
Databáze: MEDLINE
Externí odkaz: